ENVISIONING AN END TO NEURODEGENERATIVE DISEASES
ENVISIONING AN END TO NEURODEGENERATIVE DISEASES
Eikonizo is developing life-changing therapies by creating brain-penetrant small molecules to accelerate the identification of therapeutics
HDAC6 inhibitors
disease-modifying
IMAGING AGENTS
NOVEL TARGET
What we do
Our approach
Our Lead Program
Eikonizo is developing brain-penetrant small molecules to slow or stop ALS
Our Lead Program
Eikonizo is developing brain-penetrant molecule, inhibitors including Alzheimer's disease
Read More
Mechanistic Rationale
HDAC6 inhibitor treatment will improve axonal transport and reduce protein aggregates to help neurons survive
Mechanistic Rationale
HDAC6 inhibitor treatment will improve axonal transport and reduce protein aggregates to help neurons survive
Read More
Supporting Literature
Compelling evidence from multiple research groups supports Eikonizo’s approach for using HDAC6 inhibitors
Supporting Literature
Multiple research groups support Eikonizo’s approach for using HDAC6 inhibitors
Read More
Mechanistically Based
Therapeutic Development
Our brain-penetrant small molecules inhibit HDAC6, an enzyme that modifies key proteins involved in amyotrophic lateral sclerosis (ALS) and Alzheimer’s disease (AD) pathology. Inhibiting HDAC6 will preserve axonal transport and stop or slow the progression of ALS and also help neuron health in other neurodegenerative disease. Emerging data suggest HDAC6 inhibition could also prevent pathological tau phosphorylation and downstream aggregation (tangles) in AD and ‘chemo-brain’.
Our Mission
De-risk therapeutic approaches to neurodegeneration
Eikonizo is developing life-changing therapies by creating brain-penetrant small molecules and deploying in vivo target engagement techniques to accelerate the identification of therapeutics. Our first program is focused on a disease-modifying therapeutic for neurodegenerative diseases.
HDAC6 inhibitor treatment will preserve axonal transport and stop or slow the progression of AD and ALS